Background-In patients with heart failure (HF), during maximal cardiopulmonary exercise test, anaerobic threshold (AT)
T he anaerobic threshold (AT) concept is based on the principle that energy production shifts from an aerobic metabolism to a metabolism that combines both anaerobic and aerobic patterns during a progressively increasing workload exercise. 1, 2 According to the concept of threshold, the shift of metabolic pathway during incremental exercise must be more or less simultaneous among active muscular fibers. Therefore, the distribution of blood flow during exercise to and into muscles, the resistance to O 2 flow between capillaries and mitochondria, the type of muscular fibers, and their metabolic capability must be relatively homogeneous. 3 This is not always the case in patients with heart failure (HF) who have an uneven distribution of blood flow to muscles and an uneven use of O 2 , so that, for example, an important percentage of subjects with HF increase their capillary PO 2 toward the end of exercise. [4] [5] [6] [7] Inhomogeneity of blood flow distribution, of O 2 flow resistance, and of O 2 use should widen the time frame where anaerobiosis starts to develop among the muscular fibers, in few cases making the threshold indefinable. If this hypothesis is correct, then AT should be more frequently undetectable in patients with a more severe disease. 8 
Clinical Perspective on p 987
From a clinical point of view, the value of oxygen uptake (VO 2 ) at AT is used for grading the severity of HF or the effects of therapy, or to assess cardiovascular risk in case of surgery, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and it has been proposed as an alternative to peak VO 2 , being it independent of patients' motivation, exercise protocol, and exercise duration. 19 However, even in the presence of anaerobic metabolism, AT is not identified in a large number of patients with HF. 8, [20] [21] [22] It is unknown whether the finding of a reached but indeterminable AT has a clinical meaning.
The present study was therefore undertaken to assess the clinical and prognostic significance of AT detection in patients with systolic HF. To find it out, we used a multicenter HF database, generated and continuously updated by the metabolic exercise and cardiac and kidney index (MECKI) score research group. 23 
Methods Population
The study cohort consists of a population of patients with systolic HF recruited and prospectively followed up in 14 Italian HF centers (Appendix 2). At enrollment, patients were evaluated, and clinical history, laboratory, ECG, echocardiographic, and cardiopulmonary exercise test (CPET) data were collected. Study inclusion/exclusion criteria and patients' follow-up were previously described. 23 In brief, we evaluated patients with present or previous history of HF who had been in New York Heart Association functional class I to III, stable clinical conditions, and medication since ≥3 months before enrollment. Patients with comorbidities affecting exercise capacity or with exercise-induced angina or significant ECG alterations were excluded. Only patients who performed what they considered as a maximal effort were included in the original database. In the present analysis, however, to be sure that anaerobic metabolism was reached during exercise, we only evaluated patients who achieved a peak exercise respiratory quotient (RQ) >1.05.
Clinical laboratory and echocardiographic evaluations were recorded as previously described. 23 In brief, we recorded anthropometric parameters, HF pathogenesis, hemoglobin (Hb), serum sodium (Na + ), potassium (K + ), and creatinine. We calculated glomerular filtration rate by means of the modification of diet in renal disease (MDRD) formula. 24 Left ventricular volumes and ejection fraction (LVEF) were calculated by echocardiography. 25
Cardiopulmonary Exercise Tests
CPET were performed using an electronically braked cycle-ergometer or a treadmill. For comparison with cycle-ergometer, treadmill peak VO 2 data were reduced by 10%. 26 The exercise protocol was set to achieve peak exercise in 10 minutes. 19 In the absence of clinical events, CPET was self-interrupted by the patients when they stated that they had reached a maximal effort. Expiratory gases and ventilation data were recorded and analyzed breath by breath by 2 CPET experts. AT was measured by V-slope analysis of VO 2 and VCO 2 , and it was confirmed by ventilatory equivalents and end-tidal pressures of CO 2 and O 2 . 1, 27 If AT was not detected or a significant disagreement on its value was reported by ≥2 experts, AT was considered as not identified. Exercise-induced periodic breathing was defined as a cyclic fluctuation of ventilation. 28 Ventilatory efficiency (VE/VCO 2 ) slope was calculated as the linear relation slope between VE and VCO 2 from 1 minute after the beginning of loaded exercise up to the isocapnic buffering period.
Patient Grouping
Data were analyzed considering the entire population and after grouping patients according to peak VO 2 and MECKI score, a recently reported HF prognostic score that combines CPET, echocardiographic and laboratory parameters, namely peak VO 2 (%pred), VE/VCO 2 slope, LVEF, Na + , MDRD, and Hb. 23 As previously done by Wasserman et al, 29 3 peak VO 2 -based groups were defined: peak VO 2 < 12 mL/ min per kilogram, between 12 and 16 and >16. As for MECKI score, patients were divided into tertiles. Finally, we grouped patients with identified AT according to their VO 2 AT, and we compared them with patients without identified AT.
Patients' Follow-Up
Patients' follow-up was performed according to the local HF program in a theoretically endless fashion. Follow-up ended with the last clinical evaluation in the center where the patient had been recruited or with the patient's death. If the patient did not show up at the scheduled follow-up visit, they or their family were called on the phone, and their visit was rescheduled at their desire. If the patient died outside the hospital where he was followed up, we obtained medical records of the event and the cause of death. Patients who died from noncardiovascular reasons were considered censored at the time of the event. The primary end point of the study was a composite of cardiovascular death, including stroke, and urgent cardiac transplant, and the secondary end point was all-cause death.
Data Management and Analysis
Details of data management were previously reported, including a data quality control management. 23 In brief, a quality control was set up at Centro Cardiologico Monzino, where P.A. was the director of the center and responsible for data collection, while individual investigators were responsible for their own records. All investigators were experts on CPET and HF. Data collection was computerized. Quality data control included the control center staff as well as external Conclusions-The inability to identify AT most often occurs in patients with severe HF, and it has an independent prognostic role in HF. (Circ Heart Fail. 2013;6:977-987.)
Key Words: exercise ■ follow-up studies ■ heart failure ■ oxygen ■ prognosis experts (M.P. and D.M.) not involved in the recruitment of patients. All computerized data were stored on a secure network that limited access to authorized individuals. The study was approved by an institutional review committee, and the subjects gave informed consent.
Statistical Analysis
Continuous variables were presented as means±SDs, and categorical variables were presented as frequencies and percentages. Anova or unpaired t test were used as appropriate for comparison between groups, and χ 2 test was used for comparing categorical variables. Skewed distributed variables were reported as median and interquartile range and compared by the Wilcoxon signed-rank test. We used multivariable logistic regression model for evaluating, at baseline, the association between identifiable/unidentifiable AT and VO 2 and between identifiable/unidentifiable AT and MECKI score, adjusting the former for age, LVEF, MDRD, Na + , Hb, VE/VCO 2 , and periodic breathing, and the latter for age and periodic breathing.
Potential predictors of mortality were identified by univariable Cox regression analysis. A multivariable Cox proportional hazard model was used for assessing the independent prognostic value of AT adjusted for the variables significant at the univariable analysis. When MECKI score was considered in multivariable analysis, parameters generating this score were excluded. Hazard ratios and 95% confidence intervals were calculated. Kaplan-Meier survival curves were implemented for AT, and survival curves were compared using logrank test. A regression-based imputation analysis was used for missing data on Hb, Na + , and MDRD. Although there is a small difference between the percentages of missing data in the 2 groups of unidentified/identified AT, there is no relationship between AT and missing data, because of some reasons. First of all, we included AT together with age, sex, VO 2 peak (% of predicted), VE/VCO 2 slope, LVEF in the regression model. Second, a sensitivity analysis was performed to assess a model without the imputation approach, and the hazard ratio did not change, thus we can assume missing data as missing at random. The number of missing data for Hb was 289, and ≈120 for each variable for Na + and MDRD. No data were missing for the other variables. Cox regression was also performed after grouping patients according to peak VO 2 and MECKI score. A P<0.05 value considered as statistically significant. Statistical analysis was performed using SAS 9.2 (SAS Institute, Inc, Cary, NC) or IBM SPSS 20.0 (SPSS-PC+ Inc, Chicago, IL).
Results
We obtained data from 3058 patients with HF who met the study inclusion/exclusion criteria. A total of 921 cases were excluded from further analysis because their peak RQ was ≤1.05 ( Figure 1 ). The remaining 2137 patients performed CPET on a cycle-ergometer (2085 cases) or on a treadmill (52 cases). Mean follow-up was 3.4 years (range 1 day to 14 years). We observed 562 total deaths, 482 cardiovascular deaths, and 87 urgent cardiac transplants. At study enrollment, 78% of patients were treated with angiotensin I-converting enzyme inhibitors, 13% with angiotensin II receptor blockers, 80% with β-blockers, 79% with diuretics, 48% with antialdosteronic drugs, 47% with antiplatelets drugs, 31% with oral anticoagulants, 26% with digitalis, and 25% with amiodarone. Moreover, 18% of patients had implantable cardioverter-defibrillator, and 8% of patients had a cardiac resynchronization therapy. Peak VO 2 was <12 mL/ min per kilogram in 618 cases, between 12 and 16 in 798 cases, and >16 in 721 cases. Some of the most often recognized prognostic HF parameters of the entire population are reported in Table 1 . Data are mean±SD and median (interquartile ranges) for continuous variables or number (%) of subjects for categorical variables. P values were calculated by Student t test or Wilcoxon Rank-Sum Test or by χ 2 when appropriate. AT indicates anaerobic threshold; Hb, hemoglobin; LVEF, left ventricular ejection fraction; MDRD, modification of diet in renal disease; MECKI, metabolic exercise and cardiac and kidney indexes; Na + , sodium; PB, periodic breathing during exercise; VE/VCO 2 , ventilatory efficiency; and VO 2 , oxygen uptake.
*Identifies the probability of cardiovascular death or urgent cardiac transplant within 2 y. 23 Patients with peak VO 2 <12 mL/min per kilogram or in the highest MECKI tertile (≥0.104) had a more severe HF, were older, mainly male, with higher VE/VCO 2 slope, lower Hb concentration, and lower LVEF and renal function (Tables 2 and  3) . AT was not identified in 202 cases (9.45%), belonging in 110 (18%), 67 (8%), and 25 (3%) cases to group <12, 12 to 16, and >16 mL/min per kilogram, respectively (P<0.001) and 33 (17%), 50 (26%), and 112 (57%) cases to the first, second, and third tertiles of MECKI score, respectively (P<0.001). Moreover, peak VO 2 , or MECKI score, and impossibility to detect AT resulted significantly associated with univariable and multivariable logistic regression model (P<0.001), adjusting the latter for age, LVEF, MDRD, Na + , Hb, VE/VCO 2 and periodic breathing (peak VO 2 ), or for age and periodic breathing (MECKI score).
Characteristics of patients with HF according to the presence or absence of AT identification are reported in Table 1 . Patients with HF in whom AT was reached, but not detected, were older and more often female, had most often periodic breathing, higher VE/VCO 2 and MECKI score, and lower peak VO 2 , Hb, LVEF, and kidney function. In each peak VO 2 -based group, the presence of an identified/unidentified AT was associated with significant differences in measured parameters: VE/VCO 2 slope, peak VO 2 , presence of periodic breathing, and MECKI score in peak VO 2 <12 mL/min per kilogram patients, VE/VCO 2 slope, sex, presence of periodic breathing in peak VO 2 between 12 and 16 mL/min per kilogram patients; presence of periodic breathing in peak VO 2 >16 mL/min per kilogram patients (Tables 2 and 3) , all suggestive of a more severe disease in those with unidentified AT. Similarly, when grouping patients according to MECKI score tertiles, unidentified AT was associated to MECKI values suggestive of poorer prognosis (Tables 2 and 3 ).
The impossibility of identifying AT was associated to a significantly worse prognosis at Kaplan-Meier evaluation in the entire population ( Figure 2 ) and, when grouping patients, only in the group with lower peak VO 2 (<12 mL/min per kilogram) patients or in patients with the highest tertile of the MECKI score (≥0.104; Figure 3 ). Conversely, in patients with less severe exercise impairment, as those with peak VO 2 between 12 and 16 mL/min per kilogram or with peak VO 2 >16 mL/min per kilogram, or in patients with less severe HF, as those with middle or lowest MECKI score tertiles, the impossibility of identifying AT was only associated with a not significant trend toward a worse prognosis at Kaplan-Meier evaluation, likely because of the lower incidence of AT nonidentification and to the lower amount of events in these patients (Figure 3) . However, when formally tested, the interaction between AT identification and peak VO 2 or MECKI groups was not significant. Patients with HF with identified AT (n=1935) were grouped in tertiles according to VO 2 value at AT: AT ≤8.5 mL/min per kilogram (n=644), between 8.5 and 11.0 (n=640), and ≥11.0 (n=650), and those with lower VO 2 values had a worse prognosis. However, the patients with unidentified AT had the worst survival considering both end points of the study (Figure 4 ). Multivariable analysis was performed considering the variables that were linked to prognosis at univariable analysis (Table 4) . Peak VO 2 (%), VE/VCO 2 slope, Hb, Na+, MDRD, LVEF, and the impossibility of identifying AT were independently related to prognosis, regardless of the study end point considered (Table 5) . Notably, the impossibility of identifying AT maintained a significant prognostic role. A similar result was obtained including the MECKI score value in the multivariable analysis, instead of using the single variables by which the score is derived (peak VO 2 [%], VE/VCO 2 slope, Hb, Na + , MDRD, LVEF; Table 5 ). We also performed a VO 2 stratified Cox regression according to the 3 above-reported peak VO 2 classes, comparing patients with HF with unidentified versus identified AT. 
Discussion
This study shows that, in patients with HF who reached anaerobic metabolism as defined by a peak exercise RQ >1.05 during an incremental exercise, AT was not identified by standard methods in 10% of cases. This percentage was significantly higher in most patients with severe HF. The impossibility of identifying AT was associated to a worse prognosis. Notably, this impossibility maintained its negative prognostic role in HF even at a multivariable analysis, which included several HF prognostic parameters.
Defining an effort as maximal for a given individual is a matter of debate. 9 Indeed, in the absence of significant clinical events, CPET is self-interrupted by patients when they feel that they have reached a maximal effort, regardless of the encouragement to continue by the supervising medical staff. In HF, a RQ ratio >1.05 is considered as an indication of a significant effort by the patient. 30 Several prognostic studies in HF have considered CPET data as relevant, 13, 14, 18, 23, 31, 32 including VO 2 at AT. [9] [10] [11] [12] [13] [14] [15] [16] [17] 31 In the present study, we confirmed this finding. However, although anaerobic metabolism had been reached, AT was not identified in ≈10% of cases, making it difficult to allocate these patients in a specific HF or surgical risk category. Indeed, the evidence of RQ >1.05 at peak exercise of a ramp protocol exercise test implies that the anaerobic metabolism has been used to produce ATP regardless of AT identification. 3, 9 In a previous study, we showed that the impossibility of identifying AT was associated to CPET parameters suggestive of poor exercise performance. 8 However, the presence of a true maximal effort was not mandatory in that study, so that an indeterminable AT was associated, at in least in some cases, with a poor effort by the patients and a submaximal exercise. 8 Conversely, in the present study, we excluded ≈30% of patients from the analysis because RQ was ≤1.05, although they reported a maximal effort. An indeterminable AT in patients with HF who performed a maximal or nearly maximal effort and reached anaerobic metabolism was inversely related to peak VO 2 , and to HF prognosis as assessed by the MECKI score. The majority of patients with unidentified AT had peak VO 2 <12 mL/min per kilogram and a MECKI score ≥0.104. Accordingly, these patients belong to a highrisk category of HF patients, as suggested by peak VO 2 and MECKI score as well as by several other parameters (Tables  2 and 3 ). 23 The finding that the impossibility of identifying AT in patients with HF who reached anaerobic metabolism during exercise has a prognostic role is a novel observation. Most importantly, patients with an unidentified AT had a poor prognosis, worse than patients with low VO 2 at AT (≤8.5 mL/min per kilogram). Our finding extends to patients with HF who likely reached anaerobic metabolism unlike that in the previous observations by Katz et al 22 and Opasich et al, 32 who showed that peak VO 2 maintains its prognostic role even in patients with severe HF in whom AT was not detected. Indeed, conversely from Katz et al 22 and Opasich et al, 32 we have excluded subjects who, for a variety of reasons, did not perform a metabolic maximal or nearly maximal effort, and we showed a prognostic role of an unidentified AT independent of several prognostic variables including peak VO 2 . Notably, the lack of AT identification has a demonstrated negative prognostic capacity only in patients with most severe HF. Indeed, the number of cases of AT nonidentification and of events observed in our population with less severe HF ( Figure 3) was relatively small and insufficient for interaction analysis. Some technical aspects may be the reason for an undetectable AT, including a test too short to collect enough data points and a relevant hyperventilation at the beginning of exercise. The former may be because of the selection of a too demanding ramp protocol. Indeed, although the average exercise duration in patients with undetectable AT was shorter (6.23±2.51 minutes), it was long enough to allow the collection of an adequate amount of data points for AT detection. We previously showed that workload, but not VO 2 , at AT was lower in short tests (5 minutes) than in longer tests (10 and 15 minutes), but AT was identified or not identified independently of test duration. 19 Also psychogenic hyperventilation may make AT identification difficult. However, in case of hyperventilation, CO 2 storages are significantly reduced, so that RQ declines during exercise, and an RQ >1.05 is rarely observed at peak exercise. Several physiological mechanisms may also explain why AT is not identifiable: an uneven intramuscle and intermuscle distribution of blood flow during exercise, an uneven O 2 flow resistance between capillary bed and mitochondria, and the presence of muscular fibers with uneven O 2 extraction/utilization capability are the most likely. [4] [5] [6] [7] In sum, the time frame during which anaerobiosis develops in the different muscle fibers in a ramp protocol exercise becomes wide, so that a threshold shared by the majority of muscle fibers does not exist. It is therefore conceivable that the identification of AT most often lacks in patients with severe HF, who most frequently have the abovedescribed physiological impairments.
In the present study, we showed that an unidentified AT was related to several parameters suggestive of a worse prognosis, including the presence of exercise-induced periodic breathing. 14, 28 Indeed, periodic breathing may, per se, make AT identification difficult, particularly when it lasts throughout the exercise. This is the case in a minority of patients with exercise-induced periodic breathing, 33 but this information was unfortunately not available for the present data set of patients. Moreover, in 58% of cases with an unidentified AT, exercise-induced periodic breathing was not observed.
Few study limitations should be acknowledged. First, we admit that, by applying ≤1.05 as peak exercise RQ cutoff value, we likely excluded some patients with HF who had done a true maximal test. Second, because the follow-up was quite long, treatment strategies were required to be upgraded in many patients, including implantable cardioverter-defibrillator implantation and cardiac resynchronization therapy implementation, which might have, per se, influenced the prognosis. Third, several parameters known to be related to HF prognosis were not considered, such as intraventricular delay and BNP (brain natriuretic peptide) or NT-proBNP (N-terminal-proBNP) value. Fourth, we have not measured blood lactates during exercise, so that we did not evaluate whether the presence of an undetectable AT was associated to a lower or higher amount of exercise-induced lactic acid production. Finally, we have no information on reproducibility of undetection of AT.
In conclusion, we observed for the first time that the absence of an identified AT has an independent prognostic role in HF, considering several parameters related to HF prognosis at multivariable analysis either as isolated parameters or as combined in the MECKI score. This is attributable to the strong physiological meaning of an unidentifiable AT. Therefore, the VO 2 value at AT is clinically relevant in HF if anaerobic metabolism is reached, but also the finding of the impossibility of identifying AT should be carefully considered. Consequently, patients with HF with an unidentifiable AT should be considered at high risk. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 
